Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience-Reference-Cited by-同舟云学术

Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience

Published:2022-03 Issue: Volume:114 Page:106803
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

De Bellis Eleonora,Imbergamo Silvia,Candoni Anna,Liço Albana,Tanasi Ilaria,Mauro Endri,Mosna Federico,Leoncin Matteo,Stulle Manuela,Griguolo Davide,Pravato Stefano,Trentin Livio,Lazzarotto Davide,Di Bona Eros,Bassan Renato,Lucchini Elisa,Poiani Monica,Palmieri Clara,Zaja Francesco

Funder

Economic Development Board - Singapore

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference18 articles.

1. Institute NC. SEER cancer statistics review, 1975–2015: overview, median age at diagnosis. [Internet]. SEER. 2018. Available from: https://seer.cancer.gov/.

2. Acute myeloid leukemia, Version 3.2019, NCCN clinical practice guidelines in oncology;Tallman;J. Natl. Compr. Canc Netw.,2019

3. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel;Döhner;Blood,2017

4. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia;Kantarjian;Blood,2010

5. Elderly acute myeloid leukemia: assessing risk;Klepin;Curr. Hematol. Malig. Rep.,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS;Blood Neoplasia;2024-09

2. A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?;Annals of Hematology;2024-08-16

3. Safety, Efficacy, and Predictive Factors of Venetoclax-Based Regimens in Elderly Acute Myeloid Leukemia Patients: A Meta-Analysis;Clinical Lymphoma Myeloma and Leukemia;2024-08

4. Prescription patterns of venetoclax in acute myeloid leukemia;Hematological Oncology;2024-07

5. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience;Anticancer Research;2024-04-27